Publications by authors named "Naseem Jaffrani"
Article Synopsis
- Study Purpose
- : The research assessed the effectiveness of an "inclisiran first" strategy for patients with atherosclerotic cardiovascular disease who don't reach LDL-C goals, comparing this approach with usual care that only involves statins.
- Key Findings
- : 450 patients were randomized, showing that the "inclisiran first" approach resulted in a 60% reduction in LDL-C, compared to just 7% in usual care. It also helped a higher percentage of patients reach LDL-C targets (<70 mg/dL: 81.8% vs 22.2%).
- Safety and Tolerability
- : While the "inclisiran first" strategy did not lead to increased serious
MAS825, a bispecific IL-1β/IL-18 monoclonal antibody, could improve clinical outcomes in COVID-19 pneumonia by reducing inflammasome-mediated inflammation. Hospitalized non-ventilated patients with COVID-19 pneumonia (n = 138) were randomized (1:1) to receive MAS825 (10 mg/kg single i.v.
View Article and Find Full Text PDF